Expression of PD-1 by tumor-infiltrating lymphocytes (TILs) is associated with impaired effector function (cytokine production and cytotoxic efficacy against tumor cells) and/or poor outcome in several tumor types 29–32. The gene discussed is PDCD1; the disease is neoplasm.